Induced Pluripotent Stem Cell (iPSC ) Market Complete Report 2013-14
Published: February 2014 Single User PDF: US$ 3495 Corporate User PDF: US$ 5495
Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.
Š ReportsnReports.com / Contact
Induced Pluripotent Stem Cell (iPSC ) Market Complete Report 2013-14 As a provider of stem cell products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition. To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types that are showing the most promise and understand methods through which they could be commercialized. Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time. Since the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells. Today, the number of iPSC products sold worldwide is growing at an annual rate of 14.7%. In addition, 22% of all stem cell researchers now selfreport having used iPSCs within a research project. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.
Š ReportsnReports.com / Contact
Induced Pluripotent Stem Cell (iPSC ) Market Complete Report 2013-14 It is clear that iPSCs represent a lucrative product market, but methods for commercializing this cell type are still being explored, as clinical studies investigating iPSCs continue to increase in number. At this time, nearly all clinical studies involving iPSCs are for the creation and evaluation of iPSC lines from specific patient populations, in order to determine if these cell lines could be a good model for a disease of interest in that patient population. (See ClinicalTrials.gov for a current list of these trials.) Buy a copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=206575. However, the first clinical study involving transplant of iPSCs into humans began in August 2013 to investigate the use of iPSCs in treating patients with macular degeneration. This clinical study is now underway at the Riken Center in Japan, led by Masayo Takahashi. In addition, a new patent challenge has exploded on the stem cell scene. The famous “Yamanaka Patent” (U.S. Patent No. 8,058,065) for cellular reprogramming of iPSCs is now being challenged in a patent lawsuit by a group called “BioGatekeeper.” If successful in canceling the Yamanaka Patent, this could create incredible innovation in the stem cell/regenerative medicine sector.
Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.
© ReportsnReports.com / Contact
Induced Pluripotent Stem Cell (iPSC ) Market Complete Report 2013-14 Due to these exciting and rapidly changing market conditions, the infographic below explores the business of commercializing iPSCs, including the production of research products, the funding of clinical research trials, and major advances in cellular therapy and biobanking. The burgeoning iPSC product market lures major industry competitors with doubledigit growth and massive change in 2013. Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have caused great commercial interest, with potential applications ranging from the use of stem cells in reversal or treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Diseases such as Huntington’s Chorea, Parkinson’s Disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.
© ReportsnReports.com / Contact
Induced Pluripotent Stem Cell (iPSC ) Market Complete Report 2013-14 Single User License: US $ 3495; Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=206575. Discovery: Furthermore, the past twelve months have been a time of massive change for the industry. 2013 was the first year in which clinical research involving transplant of iPSCs into humans was initiated, with Masayo Takahashi of the RIKEN Center in Japan investigating the safety of iPSC-derived cell sheets in patients with macular degeneration. In another landmark event, Cellular Dynamics International (CDI) went public in July 2013 with a offering that raised $43 million dollars for the company, securing the company's position as the global leader in producing high-quality human iPSCs and differentiated cells in industrial quantities. In March of 2013, Celullar Dynamics International and the Coriell Institute for Medical Research announced receiving multi-million dollars grants from the California Institute for Regenerative Medicine (CIRM) for the creation of iPSC lines from 3,000 healthy and diseased donors, a result that will create the world’s largest human iPSC bank. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.
Š ReportsnReports.com / Contact
Induced Pluripotent Stem Cell (iPSC ) Market Complete Report 2013-14 Market Metrics - iPSC Research Products: For this reason a large and thriving research products market has grown into existence for the cell type. The number of iPSC research products sold worldwide has been growing at an annual rate of 14.7% for the past five years. In addition, 22% of all stem cell researchers now self-report as having used induced pluripotent stem cells within a research project. It is clear that iPSCs are a vital research trend within the scientific community. In summary, this is a must-read industry report for research supply companies to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the marketplace, and take advantage of crucial iPSC trends. Claim this report now to profit from this expanding market - or your competition will.
Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.
Š ReportsnReports.com / Contact
Induced Pluripotent Stem Cell (iPSC ) Market Complete Report 2013-14 Explore Report on Biotechnology Market. Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Induced Pluripotent Stem Cell (iPSC) Market Complete Report 2013-14” report OR for any other market research and intelligence needs you may have for your business.
Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.
© ReportsnReports.com / Contact